These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 27609196)

  • 1. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
    Magdy T; Burmeister BT; Burridge PW
    Pharmacol Ther; 2016 Dec; 168():113-125. PubMed ID: 27609196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
    Chang VY; Wang JJ
    Curr Oncol Rep; 2018 Apr; 20(7):52. PubMed ID: 29713898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
    Sayed N; Ameen M; Wu JC
    Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.
    Magdy T; Burridge PW
    Pharmacogenomics; 2021 Jan; 22(1):41-54. PubMed ID: 33448871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
    Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
    Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
    Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
    Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.
    Sachinidis A
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
    Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
    AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Huang MF; Pang LK; Chen YH; Zhao R; Lee DF
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
    Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
    Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
    Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
    Magdy T; Jiang Z; Jouni M; Fonoudi H; Lyra-Leite D; Jung G; Romero-Tejeda M; Kuo HH; Fetterman KA; Gharib M; Burmeister BT; Zhao M; Sapkota Y; Ross CJ; Carleton BC; Bernstein D; Burridge PW
    Cell Stem Cell; 2021 Dec; 28(12):2076-2089.e7. PubMed ID: 34525346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued exposure of anti-cancer drugs to human iPS cell-derived cardiomyocytes can unmask their cardiotoxic effects.
    Sakamoto K; Sakatoku K; Sugimoto S; Iwasaki N; Sano Y; Yamaguchi M; Kurokawa J
    J Pharmacol Sci; 2019 Aug; 140(4):345-349. PubMed ID: 31521491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
    Petrykey K; Andelfinger GU; Laverdière C; Sinnett D; Krajinovic M
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):865-883. PubMed ID: 32772754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.
    Liu S; Fang C; Zhong C; Li J; Xiao Q
    Cell Biol Toxicol; 2023 Dec; 39(6):2527-2549. PubMed ID: 37889357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity.
    Lyra-Leite DM; Burridge PW
    Curr Cardiol Rep; 2020 Jun; 22(8):56. PubMed ID: 32562096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.